MSLE

+ Watchlist + Portfolio

Satellos Bioscience Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.09
52-Week Range: $4.91 – $13.40
Market Cap: $216.09M
P/E (TTM): —
EPS (TTM): -1.95
Dividend Yield: —

Advanced Metrics

Price/Book: 3.00
PEG Ratio: —
Return on Equity: -70.45%
Return on Assets: -41.89%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 11.22
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-17.09M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $148.35M

MSLE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.75M	$6.65M	$14.36M	$18.43M
Selling, General & Admin	$2.92M	$4.57M	$5.45M	$7.44M
Operating Expenses	$6.21M	$11.66M	$20.40M	$26.46M
Operating Income	-$6.21M	-$11.66M	-$20.40M	-$26.46M
EBITDA	-$8.09M	-$11.84M	-$20.38M	-$26.45M
Pretax Income	-$8.34M	-$11.98M	-$20.63M	-$24.70M
Income Tax	$3.68K	$0.00	$0.00	$172.00K
Net Income	-$8.34M	-$11.98M	-$20.63M	-$24.87M
Diluted EPS	-2.83	-1.63	-2.16	-1.70
Diluted Shares	2.97M	7.20M	9.56M	14.60M

MSLE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.42M	$16.68M	$40.07M	$9.80M
Receivables	$191.57K	$441.00K	$435.00K	$370.00K
Current Assets	$1.65M	$30.48M	$50.74M	$31.88M
Total Assets	$4.57M	$33.49M	$50.75M	$31.89M
Current Liabilities	$2.09M	$2.73M	$3.58M	$4.11M
Total Liabilities	$2.09M	$2.73M	$3.58M	$4.11M
Retained Earnings	-$23.29M	-$36.46M	-$57.10M	-$81.97M
Shareholders' Equity	$2.48M	$30.76M	$47.16M	$27.78M
Working Capital	-$439.88K	$27.75M	$47.16M	$27.78M

MSLE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$4.26M	-$8.73M	-$18.25M	-$23.60M
Capital Expenditure	-$2.21K	-$13.57K	-$4.00K	-$6.00K
Free Cash Flow	-$4.26M	-$8.75M	-$18.26M	-$23.60M
Depreciation & Amortisation	$248.31K	$5.28K	$15.00K	$4.00K
Stock-Based Compensation	$1.06M	$1.64M	$1.64M	$3.23M
Investing Cash Flow	-$2.21K	-$13.22M	$4.66M	-$9.42M
Financing Cash Flow	$2.04M	$38.01M	$37.57M	$2.24M
Dividends Paid	$0.00	$0.00	—	—
Net Change in Cash	-$2.12M	$16.06M	$23.98M	-$30.77M

MSLE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$4.54M	$4.43M	$3.99M	$5.46M	$7.31M
Selling, General & Admin	$1.79M	$1.74M	$1.86M	$2.04M	$2.35M
Operating Expenses	$6.48M	$6.37M	$5.97M	$7.65M	$10.04M
Operating Income	-$6.48M	-$6.37M	-$5.97M	-$7.65M	-$10.04M
EBITDA	-$6.48M	-$6.37M	-$5.96M	-$7.65M	-$10.04M
Pretax Income	-$6.08M	-$5.58M	-$5.80M	-$7.25M	-$9.73M
Income Tax	$63.00K	$32.00K	$19.00K	$58.00K	$33.00K
Net Income	-$6.14M	-$5.61M	-$5.82M	-$7.30M	-$9.77M
Diluted EPS	-0.44	-0.36	-0.36	—	-0.53
Diluted Shares	13.82M	14.27M	13.94M	—	18.44M

MSLE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$32.71M	$38.22M	$19.30M	$9.80M	$18.70M
Receivables	$338.00K	$186.00K	$205.00K	$370.00K	$726.00K
Current Assets	$44.37M	$41.11M	$37.50M	$31.88M	$75.22M
Total Assets	$44.37M	$41.12M	$37.50M	$31.89M	$75.23M
Current Liabilities	$2.70M	$2.77M	$3.50M	$4.11M	$4.56M
Total Liabilities	$2.70M	$2.77M	$3.50M	$4.11M	$4.56M
Retained Earnings	-$63.24M	-$68.85M	-$74.67M	-$81.97M	-$91.74M
Shareholders' Equity	$41.67M	$38.35M	$34.00M	$27.78M	$70.66M
Working Capital	$41.67M	$38.34M	$33.99M	$27.78M	$70.66M

MSLE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.37M	-$4.84M	-$4.13M	-$7.26M	-$9.59M
Capital Expenditure	—	—	-$3.00K	—	-$4.00K
Free Cash Flow	-$7.37M	-$4.85M	-$4.13M	-$7.26M	-$9.59M
Depreciation & Amortisation	$1.00K	$0.00	$3.00K	$0.00	$1.00K
Stock-Based Compensation	$642.00K	$834.00K	$774.00K	$985.00K	$727.00K
Investing Cash Flow	$0.00	$8.47M	-$15.33M	-$2.56M	-$33.34M
Financing Cash Flow	$2.00K	$1.39M	$700.00K	$147.00K	$51.90M
Net Change in Cash	-$7.36M	$5.02M	-$18.76M	-$9.67M	$8.98M

Market Snapshot

About

Satellos Bioscience Inc. is a clinical-stage biotechnology company developing regenerative medicines for muscle diseases and injuries. The company focuses on muscle stem cell biology to create therapies that restore muscle function in patients with muscular dystrophies and age-related muscle loss. Its lead programs target conditions with significant unmet medical needs.